The data are encouraging for Plinabulin's potential in post-ICI NSCLC, but the study is a single-arm Phase 2 with 47 patients. Traders should watch for next steps: regulatory discussions, Phase 3 plans, or partnership announcements. Given BYSI's small market cap and historical volatility, a binary outcome on future catalysts could drive large moves.
Price Chart
Executive Summary
BeyondSpring presented updated Phase 2 data at ASCO 2026 for its triple combination (pembrolizumab + Plinabulin + docetaxel) in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors. The data showed median PFS of 7.0 months, a 24-month OS rate of 58.0%, and a manageable safety profile, which the company positions as favorable versus historical docetaxel benchmarks. As a clinical-stage biotech with a $72M market cap, this is a positive data readout but remains early-stage, and the stock has historically shown high volatility on such news.
Key Facts
- Median PFS of 7.0 months vs historical 3.7-3.9 months for docetaxel in similar post-ICI populations.
- 24-month OS rate of 58.0% with median OS not yet reached.
- Disease control rate (DCR) of 79.5% and confirmed ORR of 18.2%.
- 53.2% of patients experienced grade 3+ treatment-related adverse events, with hypertension (17.0%) and neutropenia (17.0%) most common.
- Data presented at ASCO 2026, a key medical conference, lending credibility to the results.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue. Positive data may increase probability of future regulatory success and partnership value.
Risk Factors
- Single-arm Phase 2 design limits comparability; results may not replicate in larger randomized trials.
- 53.2% grade 3+ AE rate, including neutropenia and hypertension, could raise safety concerns.
- No revenue or near-term approval timeline; stock is highly sensitive to pipeline milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304984 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4621 (−28.36%) |
Oct 2, 2026 25d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4621 (+41.21%) |
Sep 29, 2026 28d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4621 (−40.24%) |
Sep 29, 2026 28d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4621 (+40.24%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4621 (+37.55%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4621 (−25.24%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4621 (−35.05%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4621 (−35.05%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4621 (−72.98%) |
Jun 2, 2026 21w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4621 (−72.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers